ReviewCurrent neurology and neuroscience reports2012
Thyroid eye disease: towards an evidence base for treatment in the 21st century.
Review in Current neurology and neuroscience reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Immunomodulators in Graves' ophthalmopathy: a systematic review.Frontiers in endocrinology · 2026Pooled it
- Teprotumumab's Impact on Proptosis in Long-duration Thyroid Eye Disease: A Systematic Review and Meta-analysis.TouchREVIEWS in endocrinology · 2024Pooled it
- Patients with Thyroid Eye Disease Initiating Teprotumumab: A Real-World Cohort Study Using the Linked IRIS-Komodo Database.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials.Ophthalmology and therapy · 2025Article
- Teprotumumab for thyroid eye disease in patients with hypothyroid/euthyroid state: a multicenter case series.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Deep learning methods for diagnosis of graves' ophthalmopathy using magnetic resonance imaging.Quantitative imaging in medicine and surgery · 2024Article
- Weak acid-initiated slow release of Dexamethasone from hydrogel to treat orbital inflammation.Theranostics · 2023Article
- Update on the surgical management of Graves' orbitopathy.Frontiers in endocrinology · 2022Review
- Insights into Current Management Strategies for Dysthyroid Optic Neuropathy: A Review.Clinical ophthalmology (Auckland, N.Z.) · 2022Review
- A data-driven approach for the discovery of biomarkers associated with thyroid eye disease.BMC ophthalmology · 2021Article
- Graves' Orbitopathy: Report of 82 cases.La Tunisie medicale · 2021Article
- MicroRNA-130a Is Elevated in Thyroid Eye Disease and Increases Lipid Accumulation in Fibroblasts Through the Suppression of AMPK.Investigative ophthalmology & visual science · 2021Article
- Etiologies of Proptosis: A review.Internal medicine review (Washington, D.C. : Online) · 2020Article
- Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm.Therapeutics and clinical risk management · 2019Review
- Intraoperative relaxed muscle positioning technique results in a tertiary Center for Thyroid Orbitopathy Related Strabismus.BMC ophthalmology · 2018Article
- Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management.Expert review of ophthalmology · 2017Article
- Short and long-term effects of high-dose intravenous methylprednisolone pulse therapy on thyroid-associated ophthalmopathy.Experimental and therapeutic medicine · 2016Article
- Selenium supplementation in thyroid associated ophthalmopathy: an update.International journal of ophthalmology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Thyroid eye disease (TED) is the most common extrathyroidal manifestation of Graves' disease. Incomplete understanding of its pathogenesis has hindered development of targeted therapies that might alter the natural course of disease. Smoking cessation and maintenance of euthyroidism appear to reduce the rate of onset and severity of TED. Recent evidence suggests that selenium may lessen the inflammatory symptoms in mild disease. Corticosteroids remain the primary treatment for patients with moderate to severe active TED. Surgical decompression is commonly undertaken in the chronic stable phase, and only rarely in the active phase when vision is threatened by compressive optic neuropathy. Orbital radiotherapy remains an adjunctive strategy during active disease. Targeted immunotherapies have the potential to alter disease progression, but further evidence is needed to establish safety and efficacy. In this article, we review evidence from prospective therapeutic trials of several treatment modalities. We focus on moderate to severe active TED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.